Overview Pegcetacoplan (APL-2) in Neovascular AMD Status: Terminated Trial end date: 2019-04-05 Target enrollment: Participant gender: Summary Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD Phase: Phase 1/Phase 2 Details Lead Sponsor: Apellis Pharmaceuticals, Inc.